Clinical trials: Primary Headache Disorders
Migraine Disorders
Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.
- Trial name
- NP101-011 (NCT00723983)
- Testing
- Sumatriptan succinate, NP101 Study Patch
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NuPathe Inc.
Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17.
- Trial name
- PIONEER-PEDS2 (NCT04396574)
- Testing
- Lasmiditan
- Where
- 134 sites in United States, Belgium and 13 more
- Volunteers
- 558 people
- Sponsor
- Eli Lilly and Company
Migraine
Optical Treatment of Migraines Using the Avulux™ Optical Filter in the Form of Spectacle Lenses.
The primary objective of this study is to evaluate the efficacy of the Avulux device in reducing the impact of migraine headaches as measured by improvement in Headache Impact Test (HIT-6TM) scores at three weeks when compared to…
- Trial name
- NCT03902496
- Testing
- HIT-6 Questionnaire, Avulux Spectacles
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Avulux, Inc.
Migraine
Continuous Treatment Study of Topiramate in Migraine Participants
The purpose of this study is to evaluate the safety and efficacy of topiramate in participants with migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting and constipation or…
- Trial name
- NCT01799590
- Testing
- Topiramate
- Where
- 25 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Janssen Pharmaceutical K.K.
Migraine Disorders, Headache Disorders
Therapy for Migraine Prevention in Children 6-11 Years of Age
The aim of this study is to evaluate the effect of SPN-538 for the prophylaxis of migraine in pediatric patients 6 to 11 years old.
- Trial name
- NCT04050293
- Testing
- SPN-538
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Migraine Disorders
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
The purpose of this study is to investigate the effects of erenumab on central sensitization and brain networks connectivity of migraine patients
- Trial name
- RESET BRAIN (NCT03977649)
- Testing
- erenumab
- Where
- 5 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Insomnia, Migraine
Treatment of Insomnia in Migraineurs
It is hypothesized that treating insomnia in migraineurs, many of whom also have tension headaches, prolongs total sleep time to the extent that it decreases overall headache frequency.
- Trial name
- NCT00812214
- Testing
- eszopiclone
- Volunteers
- 113 people
- Sponsor
- MedVadis Research Corporation
Migraine
Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine
To evaluate the effects of a single sc administration of TEZAMPANEL at one of three different dosage levels compared to placebo, employing traditional measures of efficacy and safety in the treatment of a single episode of acute…
- Trial name
- NCT00567086
- Testing
- TEZAMPANEL
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- TorreyPines Therapeutics
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- NCT06004388
- Testing
- Click Digital Therapeutic
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Click Therapeutics, Inc.
Migraine Disorders
Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®
This study will prospectively assess long term heath related quality of life in chronic migraine patients currently being treated with OnabotulinumtoxinA for injection (BOTOX®) as standard of care.
- Trial name
- PREDICT (NCT02502123)
- Testing
- No Intervention
- Where
- 15 sites in Canada
- Volunteers
- 215 people
- Sponsor
- Allergan
Headache Disorders, Primary, Migraine With Aura
IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headaches are a common medical problem that physicians frequently encounter in their practice. One of key findings of The Atlas of Headache Disorders prepared by World Health Organization (WHO) is: headache disorders, including…
- Conditions
- Headache Disorders, Primary, Migraine With Aura, Migraine Without Aura, Tension-Type Headache
- Trial name
- PRESTO (NCT02115269)
- Where
- 30 sites in Kazakhstan, Ukraine
- Volunteers
- 759 people
- Sponsor
- Abbott
Chronic Migraine or Episodic Migraine
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.
- Trial name
- NCT03238781
- Testing
- AMG 301
- Where
- 49 sites in United States, Austria and 6 more
- Volunteers
- 343 people
- Sponsor
- Amgen
Migraine
Acute Treatment Trial in Adult Subjects With Migraines
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
- Trial name
- NCT03872453
- Testing
- Zavegepant, Intranasal Aptar Pharma Unit Dose System
- Where
- 82 sites in United States
- Volunteers
- 2,154 people
- Sponsor
- Pfizer
Migraine Disorders
A Study of LY2951742 in Healthy Japanese and Caucasian Participants
The main purpose of this study is to evaluate the safety of the study drug known as LY2951742 in healthy Japanese and Caucasians. The study will also investigate how the body processes the drug and how the drug affects the body.
- Trial name
- NCT02104765
- Testing
- LY2951742
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine.
- Trial name
- NCT00442936
- Testing
- Telcagepant potassium 150 mg, Telcagepant potassium 300 mg, Zolmitriptan 5 mg
- Volunteers
- 1,380 people
- Sponsor
- Merck Sharp & Dohme LLC
Episodic Migraine
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have failed other preventive migraine treatments.
- Trial name
- NCT03096834
- Testing
- AMG334 (70 mg) Pre-Filled Syringe (PFS)
- Where
- 59 sites in Australia, Austria and 14 more
- Volunteers
- 246 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)
The purpose of this study is to investigate the safety and tolerability of telcagepant (MK-0974) in the long-term treatment of acute migraine in adult participants.
- Trial name
- NCT00443209
- Testing
- Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets
- Volunteers
- 1,068 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Disorders, Migraine
Prevention Study in Adult Patients Suffering From Migraine Headaches
Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache.
- Trial name
- NCT00742209
- Testing
- GSK1838262
- Where
- 59 sites in United States, Canada
- Volunteers
- 526 people
- Sponsor
- XenoPort, Inc.
Migraine
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
This will be a randomized, single dose, double-blind, placebo-controlled, Latin-square design with 5-period (full) crossover study with participants randomized to treatment sequences. Participants will complete all 5 Periods.
- Trial name
- NCT03012334
- Testing
- Lasmiditan, Alprazolam
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine, Headache
Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches
The purpose of this study is to compare the effectiveness and safety of two treatment regimens in preventing migraines. The antidepressant amitriptyline has been used successfully to prevent migraine headaches.
- Trial name
- NCT00210821
- Testing
- topiramate
- Volunteers
- 347 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.